NYSE: EHC · Medical Care Facilities
Encompass Health (EHC) fair value: undervalued or overvalued?
As of 31 Oct 2026, Faircurve's model values Encompass Health (EHC) at $159.65 a share. The stock last closed at $141.27, which puts the model's fair value 13.0% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 5 Nov 2026. Encompass Health Corporation.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 31 Oct 2026 moved the fair value from $149.41 to $159.65 (+6.9%). The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move.
What the model makes of itThe price of $141.27 is 13.0% below it: Fairly valued, on a medium evidence grade.
What's nextNext report on 4 Feb 2027. Options prices imply a move of about 9% either way over the next month. On the model's Scorecard Leaders list since 26 Oct 2026 (a strategy with a proving record). The next weekly run is on Saturday 7 Nov 2026.
What price range does the model give EHC?
The calibrated range for EHC over 63 trading days is $128.84 to $158.19. It sits around the last close, and its width comes from the volatility that EHC's own options imply (31% a year), calibrated weekly against realised prices (n = 6,661 past valuations, refreshed 31 Oct 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $127.65 to $197.17. In 72% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 31 Oct 2026
Encompass Health Corporation (EHC) delivers post-acute healthcare services across the United States, in dedicated facilities and in patients' homes.
Faircurve's model gives a fair value of $159.65 a share on 31 Oct 2026, the midpoint of 2,000 simulations. The previous run, on 24 Oct 2026, gave $149.41, so the fair value moved +6.9%. In the model's own words, the stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The calibrated range over 63 trading days is $129.85 to $156.09, built around the price from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon, across 6,661 past valuations. The evidence grade is Medium. It reflects input completeness, the number and agreement of comparable companies, and the spread of outcomes. It does not say whether the fair value is right.
Encompass Health scores 67 out of 100 on the model's overall quality score, a composite of six factors measured against comparable companies. Profitability is the strongest, at 83, with ROIC of 14.7% against a peer median of 8.6%. The balance sheet scores 70, with net debt to EBITDA of 1.76x against a peer median of 4.74x. The model compares it with DaVita, The Ensign Group, Universal Health Services, Tenet Healthcare, Chemed, Hims & Hers Health, Concentra and Option Care Health.
Written from the figures on this page for the 31 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does EHC report earnings, and how has the stock reacted?
Encompass Health's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.
Options prices on 5 Nov 2026 imply a move of about 8.4% in either direction through the nearest expiry, about 42 days out. That is the size the market is pricing, not a direction. EHC's 30 day implied volatility works out to about 8.9% over one month.
On 4 Nov 2026 EHC moved 4.6% in one session, against the 1.9% a day that options had priced: 2.4 times the implied size.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across EHC's last 8 reports, ignoring direction, was 7.2%.
What the options market has priced for a month's move in EHC
How does EHC score on business quality?
Encompass Health's overall quality score is 67 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 83 | 14.7%ROIC | 8.6% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 66 | 0.71xFCF / net income | 0.89x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 52 | 10.5%Revenue growth, trailing | 20.2% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 44 | 2.1%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 70 | 1.76xNet debt / EBITDA | 4.74x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 69 | 0.9 ptsEBITDA margin downside volatility, 5y | 1.2 pts |
How does EHC compare with similar companies?
The companies in medical care facilities closest to Encompass Health in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| DVA DaVita Inc. | $194.82 | $207.11 | +6.3% | Fairly valued |
| ENSG The Ensign Group, Inc. | $182.39 | $170.48 | -6.5% | Fairly valued |
| UHS Universal Health Services, Inc. | $198.59 | $284.60 | +43.3% | Undervalued |
| THC Tenet Healthcare Corporation | $286.46 | $375.62 | +31.1% | Undervalued |
| CHE Chemed Corporation | $533.77 | $563.60 | +5.6% | Fairly valued |
| HIMS Hims & Hers Health, Inc. | $24.06 | $28.40 | +18.0% | Undervalued |
| CON Concentra Group Holdings Parent, Inc. | $42.15 | $42.06 | -0.2% | Fairly valued |
| OPCH Option Care Health, Inc. | $31.50 | $33.38 | +6.0% | Fairly valued |
What the comparable companies' multiples alone would give for EHC, the peer-implied price, is $222.86 a share on this run. The fair value weighs that against the company's own multiple.
All medical care facilities stocks ranked by gap to fair value
Encompass Health at a glance
Encompass Health Corporation delivers a range of post-acute healthcare services across the United States, offered both in dedicated facilities and directly within patients' homes.
- Market value
- $13.4B
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Revenue expected, next twelve months
- $6.9B
- Consensus revenue growth, next fiscal year
- +9.1%
- Analysts with estimates
- 7
- Beta to the US market
- -0.18
- First valued by Faircurve
- 11 Jul 2026
At the close of 5 Nov 2026, 56.0% of the 1,065 graded US stocks the model covers traded below the model's fair value. EHC was among them.
How the fair value is worked out: the model prices Encompass Health on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 24 Oct 2026 the model's fair value for EHC was $149.41. As of 31 Oct 2026 it is $159.65, a change of +6.9%. The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Encompass Health's valuation
Is Encompass Health stock undervalued or overvalued?
On Faircurve's model, EHC reads as Fairly valued as of 31 Oct 2026. The model's fair value is $159.65 a share against a last close of $141.27, a gap of +13.0%.
What is EHC's fair value?
$159.65 a share as of 31 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $127.65 to $197.17.
What price range does the model give EHC?
$128.84 to $158.19 over 63 trading days. Ranges built this way held the price 60% of the time across 6,661 past valuations, refreshed 31 Oct 2026.
When does Encompass Health report earnings next?
The next report is scheduled for 4 Feb 2027. Companies can move their dates.
How much has EHC moved on past earnings reports?
Across its last 8 reports the median two session move was 7.2%, ignoring direction. The largest was +13.0% around the report of 5 Aug 2026.
How confident is the model in this valuation?
The model's evidence grade for EHC is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on EHC
The model has an idea open on EHC under Scorecard Leaders since 26 Oct 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on EHC with their outcomes. A free account is enough.